Contents
Sources checked September 30 to October 1, 2026.
Most publicly funded cancer research in the United States flows through one federal agency, the National Cancer Institute (NCI). Part of the National Institutes of Health, NCI is the federal government's main agency for cancer research and training [1]. Congress funds it each year, and in fiscal year 2025 it had a budget of $7.22 billion [2]. Most of that money goes out as grants and cooperative agreements to universities, hospitals and research centers, and the rest supports NCI's own laboratories [1][2].
NCI's mission is to lead and support cancer research so that people live longer, healthier lives [1]. Its national clinical trial network is meant to complement industry, not duplicate it, by taking on questions companies are less likely to fund: radiation and surgery trials, studies of whether less treatment works as well as more, trials in children and young adults, and trials in rare cancers [3]. NCI also wants patients to be able to join trials no matter where they live [4].
Clinical trials are one part of that research, and they run on a system that can be hard to follow from the outside. NCTN, ETCTN, NCORP, CTSU, LAPS, SWOG and NRG each name a different piece, and the names blur together quickly. Our goal with this article is to demystify that system. We follow the money from Congress to the bedside and explain, in plain terms, who pays, who organizes the work, which hospitals take part, and how a publicly funded trial reaches a patient.
Untangling the Acronyms: The Main NCI Trial Networks
NCTN: the National Clinical Trials Network
The National Clinical Trials Network (NCTN) is a group of organizations and clinicians that coordinates and supports cancer clinical trials at somewhere between 2,200 and 3,000 sites across the United States, Canada and other countries, depending on the source [7][5].
The NCTN replaced NCI's older Cooperative Group program in 2014, combining nine adult groups into four and adding one pediatric group [3][8]. Its focus is large, late-phase treatment and imaging trials, mainly phase II and phase III studies [3][5]. These trials compare a new treatment against the current standard and can enroll anywhere from 100 to several thousand patients [9].
The NCTN research groups
The NCTN works through five US research groups, four adult and one pediatric [10]. The groups do not treat patients. They design the trials, write the study protocols, monitor safety and analyze the results [10], while the hospitals and clinics that belong to each group enroll patients and deliver their care. Each group publishes a directory of its member sites, and most identify each site by its CTEP ID. CTEP, NCI's Cancer Therapy Evaluation Program, is the part of the Division of Cancer Treatment and Diagnosis that oversees the NCTN and assigns these site codes [3][11].
1. Alliance for Clinical Trials in Oncology
The Alliance describes itself as part of the NCTN sponsored by NCI, uniting more than 25,000 cancer specialists at 115 main institutions [12]. It also describes itself as a leading research base for NCORP and reports enrolling more than 40,000 participants [12]. Its mission covers multidisciplinary cancer control, prevention and treatment trials [12].
The Alliance's public Member Institutions page is organized by state or province and then by city. It states that main member institutions may have affiliates that are not listed, and it shows no CTEP IDs [13]. That makes it a useful map of main members and an incomplete roster of sites.
2. ECOG-ACRIN Cancer Research Group
ECOG-ACRIN was formed in May 2012 by a merger of the Eastern Cooperative Oncology Group, a therapy-focused group, and the American College of Radiology Imaging Network, an imaging-focused group, both NCI-sponsored cooperative groups [14]. It describes itself as a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of cancer, and its distinguishing strength is imaging and biomarker science [15]. It integrates imaging and pathology-based biomarker discovery into treatment research and also runs imaging-specific trials for prevention, screening and treatment [15].
ECOG-ACRIN reports nearly 1,400 academic and community cancer centers and hospitals and about 21,000 oncology professionals, and names NCI as its primary funder through the NCTN and NCORP [15]. Its participating-institutions directory is searchable by country, state and institution, or by distance from a location. Each listing shows an NCI-CTEP ID, an "NCI-Member Type" and a separate "ECOG-ACRIN Member Type" [16]. Two membership labels on one record show that NCI's classification of a site and a group's classification of the same site are different things.
3. NRG Oncology
NRG Oncology was formed by bringing together three long-established research organizations: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG) [17]. NRG says its legacy groups have more than 150 years of combined experience running multi-institution phase II and III trials sponsored mainly by NCI [17]. It conducts phase I, II and III trials and translational studies across breast, gynecologic, gastrointestinal, lung, brain, head and neck, and genitourinary cancers [17].
NRG publishes the most granular roster of the groups we compared. Its Member Institution Lists page offers rosters by network and state, by CTEP ID, and as a combined list of Main Member, LAPS and NCORP sites, plus a voting member roster [18]. The combined list is dated July 1, 2026, and its columns include CTEP ID, institution name, city, state or province, and member role [19].
4. SWOG Cancer Research Network
SWOG began in 1956 in Houston, founded by pediatrician Grant Taylor under an NCI program, as the Southwest Cancer Chemotherapy Study Group. It became the Southwest Oncology Group and adopted its current name in 2018 [20]. It is one of the five US NCTN groups [10]. SWOG says it was the first NCTN member to partner with basic science centers [21].
By SWOG's own account, more than 1,300 institutions and over 20,000 individual members have joined, from large urban cancer centers to small rural hospitals [21]. SWOG credits its trials with contributing to FDA approval of 15 cancer therapies [20], a self-reported figure.
SWOG publishes a searchable institution directory that can be filtered by state and by institution type (Main, split into LAPS and non-LAPS, plus NCORP, Affiliate, Foreign, Special and VA). Each entry carries an NCI code and a SWOG institution number [22].
5. Children's Oncology Group (COG)
The Children's Oncology Group is the NCTN's pediatric group [10]. COG describes itself as a research network focused on improving outcomes for children, adolescents and young adults with cancer, bringing together more than 220 hospitals and more than 13,500 researchers, clinicians and specialists [23]. Its public member-institution directory can be filtered by country and state and shows each institution's address and a CTEP ID [24].
LAPS: the academic hospitals behind the groups
LAPS, or Lead Academic Participating Sites, are academic cancer centers that NCI funds directly to anchor enrollment in NCTN trials. To qualify, an institution needs a fellowship training program and a track record of enrolling large numbers of patients [10]. Each LAPS helps design and lead trials with one or more of the adult research groups, and is expected to enroll patients across the whole network [25]. For March 2026 to February 2032, 32 institutions hold LAPS grants, including Johns Hopkins, Memorial Sloan Kettering, MD Anderson, Mayo Clinic, Duke, Yale and Washington University in St. Louis [10].
Not every hospital can apply. A LAPS must be a single academic hospital or clinic program under one financial and governance structure, and it cannot also be an NCORP community site [25].
LAPS are institutions, not research groups, but the label also shows up in group rosters. NRG lists LAPS as a member role [19], SWOG separates LAPS from other main members [22], and ECOG-ACRIN gives LAPS administrative records their own IDs alongside the hospital's ordinary record [16].
ETCTN: the Experimental Therapeutics Clinical Trials Network
The Experimental Therapeutics Clinical Trials Network (ETCTN) does a different job from the NCTN. Created in 2014 and managed by CTEP, it runs early-phase trials of new cancer drugs and drug combinations [26]. These trials test whether new combinations are safe, look for early signs that they work in targeted groups of patients, and study biomarkers in depth [27]. The most promising treatments can move on to larger trials funded by NCI or by private companies [5].
The ETCTN is organized around eight lead academic organizations. Each one works with its own affiliated sites, 43 in total [27]:
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Harvard Cancer Center
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
- Ohio State University Comprehensive Cancer Center
- Princess Margaret Cancer Centre, University Health Network
- UPMC Hillman Cancer Center
- University of Texas MD Anderson Cancer Center
- Yale Cancer Center
NCORP: the NCI Community Oncology Research Program
The NCI Community Oncology Research Program (NCORP) brings cancer clinical trials to patients where they already get care: community hospitals and oncology practices, not large academic centers [4]. Run by NCI's Division of Cancer Prevention [28], it focuses on prevention, screening, supportive care and care delivery research, and its sites also enroll patients in NCTN treatment and imaging trials [4]. In practice, a patient in a mid-sized city can join an NCI-supported trial without traveling hours to an academic center.
NCORP has three parts, as of NCI's latest count [4]:
- Research bases (7) design the trials and provide scientific and statistical leadership.
- Community sites (32) are groups of community hospitals and oncology practices that enroll patients.
- Minority and underserved community sites (14) serve populations that are at least 30 percent racial or ethnic minorities or rural residents.
Together they reach more than 1,000 affiliated locations across 44 states, the District of Columbia, Puerto Rico and Guam [4]. NCI's Find a Site tool lists each site and its affiliates [29].
The program is also growing. A new type of award, NCORP Academic Community Sites, in which an academic center leads a network of community hospitals and practices, is expected to begin in July 2027 [30].
CTSU: the shared infrastructure
The Cancer Trials Support Unit (CTSU) is not a research group. It does not design trials, and sites do not join it the way they join SWOG or NRG. It is the shared service that gives qualified sites access to NCI-funded trials and handles the work of taking part, with one approach to regulatory requirements and patient enrollment across all the networks [5][31]. It does three main jobs [31]:
- Enrollment. Credentialed site staff enroll eligible patients through one system, the Oncology Patient Enrollment Network (OPEN).
- Regulatory and site support. CTSU helps sites with the steps needed to open and run network trials, and its website and training platform are the central resource for site staff [5][31].
- Safety reporting. Its data system links directly to CTEP's adverse event reporting.
Ethics review is handled separately, by the NCI Central Institutional Review Board (CIRB). US sites must use it as the review board for network trials, and it serves more than 1,800 institutions [31][32].
In short: a research group such as SWOG designs and leads a trial, with CTEP approving the protocol [33]. The CIRB reviews the trial's ethics. CTSU is the system sites use to take part.
Who Pays for What in a Publicly Funded Trial
A publicly funded trial is rarely paid for by a single source. The money comes from three places, and each one covers a different part of the work.
NCI funding. NCI pays each network differently. In the NCTN, awards fund the research groups' operations and statistics centers, while separate LAPS grants go directly to 32 academic institutions [7][3][10][25]. Other hospitals that enroll patients in NCTN trials are paid through research reimbursement from the group they belong to [7]. NCORP works differently: community hospitals and practices receive their own NCORP awards [7]. In the ETCTN, grants go to the eight lead academic organizations, which work with their affiliated sites [27].
Sponsor and industry funding. The public networks do not work in isolation. Promising treatments identified in ETCTN trials can move into late-stage trials funded by NCI or by private companies [5].
Patient care versus research costs. Within a single trial, costs are split. Standard care the patient would need anyway is often billed to health insurance, while research costs, such as the study drug or research-only tests, may be covered by the trial's sponsor [35].
One Hospital, Several Affiliations
A single hospital can hold several roles at once, and each one is granted separately [10][27]. Some roles are awarded by NCI and mean the same thing across the networks: LAPS, ETCTN lead and affiliate organizations, and NCORP sites [10][27][4][29]. Others are granted by each research group, which sets its own membership rules and labels [34]. Not every combination is allowed: NCI's LAPS funding notice barred NCORP-funded community sites from applying [25]. The flow below shows how to piece a hospital's affiliations together.
The CTEP site code is what ties the sources together. The same institution can appear under several names, but each clinical site in NCI-sponsored trials carries one code [11]. The groups show it under their own labels [22][19][16][24], and the Alliance does not show it at all [13]. Two cautions apply. A hospital missing from a list is unconfirmed, not ruled out. And ClinicalTrials.gov shows where a trial recruited [36], not whether a site belongs to any network [34].
Why Affiliations Matter for Site Selection
For a sponsor or CRO choosing where to run a cancer trial, a hospital's network affiliations are some of the most useful early signals available. They hint at four things:
- Disease focus. Each group leans toward certain areas: NRG toward radiation, gynecologic and brain cancers [17], ECOG-ACRIN toward imaging and biomarkers [15], and COG toward children and young adults [23]. A site's group ties point to where its investigators and patients are.
- Readiness. Network sites already work to NCI standards and use shared systems such as CTSU and the Central IRB [31][32], which can shorten study start-up.
- Reach. NCORP and community affiliates bring trials to patients outside major academic centers [4], which matters for sponsors trying to enroll a broader population.
- Competing work. A site heavily involved in group trials for the same cancer may have fewer patients left for a new study.
The group name alone does not decide what a site can run. Membership in any one NCTN group lets a site join trials led by any group [34]. Affiliation is a starting signal, not proof of capacity.
That is why accurate data matters. When affiliation data is wrong or incomplete, sponsors make choices on a false picture:
- An affiliate counted as a full member, or a health system's status credited to a single campus, can make a site look more capable than it is.
- An old roster can point to relationships that have already ended.
- Directories that leave out affiliates can hide good community sites entirely.
- A ClinicalTrials.gov listing mistaken for membership can suggest experience the site does not have.
Public sources have gaps of their own: site counts differ between pages, some directories are undated or list only main members, and some labels are not defined [7][5][16][13]. Each gap has a cost: sites that start slowly, enroll fewer patients than planned, or are missed altogether.
That is why Kitsa built KScout. KScout is our clinical trial site intelligence tool. It brings the official NCI and research group rosters together in one place, so you can see each site and all of its affiliations at a glance, alongside the feasibility signals sponsors use to build a shortlist. Explore the sites in each network:
- Alliance for Clinical Trials in Oncology
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
- SWOG Cancer Research Network
- Children's Oncology Group
- LAPS: Lead Academic Participating Sites
- ETCTN: Experimental Therapeutics Clinical Trials Network
- NCORP: NCI Community Oncology Research Program
KScout helps you shortlist faster. Final site choices should still be confirmed against the official sources and the site itself.
Key Takeaways
- NCI, part of NIH and funded by Congress, is the main source of public money for cancer clinical trials in the United States, with a budget of $7.22 billion in fiscal year 2025.
- NCI funds three main trial networks with different jobs: the NCTN for large late-phase trials, the ETCTN for early-phase drug trials, and NCORP for trials in community hospitals and practices.
- The NCTN works through five US research groups (Alliance, ECOG-ACRIN, NRG Oncology, SWOG and COG), supported by 32 LAPS academic centers that anchor enrollment.
- CTSU and the NCI Central IRB are shared services, not research groups. CTSU handles enrollment and site support, and the CIRB handles ethics review.
- NCI pays each network differently. Within a trial, insurance often covers routine care, while the sponsor covers research costs such as the study drug.
- One hospital can hold several roles at once, each granted separately. The CTEP site code is the most reliable way to match a site across directories.
- For sponsors, affiliations are a useful early signal of disease focus, readiness and reach, but not proof of capacity, so they should always be checked against official sources.
FAQ
Who pays for NCI-supported cancer clinical trials?
Congress funds NCI, and NCI pays each network differently. NCTN awards fund the research groups, LAPS grants go to academic sites, and community hospitals are paid through group reimbursement or their own NCORP awards. Within a trial, routine care is often billed to insurance, while research costs such as the study drug may be covered by the sponsor.
What is the difference between NCTN, ETCTN, NCORP and LAPS?
The NCTN runs large, late-phase treatment and imaging trials through five US research groups. The ETCTN runs early-phase trials of new drugs through eight lead academic organizations. NCORP brings prevention, screening, supportive care and treatment trials to community hospitals. LAPS are not a network: they are 32 academic institutions that NCI funds directly to lead enrollment for the adult NCTN groups.
Can one hospital belong to more than one network or group?
Yes. A hospital can be a member of several NCTN groups, hold a LAPS grant, and lead or join the ETCTN, with each role granted separately. Some combinations are restricted, and each group sets its own membership rules.
Does belonging to an NCTN group mean a site can run any trial?
Membership in any one NCTN group lets a site join trials led by any group, as long as its investigators are qualified. But membership does not mean the site is open, approved or has the capacity for a specific study. That has to be confirmed trial by trial.
Can I rely on ClinicalTrials.gov to tell me which network a site belongs to?
No. ClinicalTrials.gov shows where a trial recruited, based on what the study sponsor entered. It does not show group membership, LAPS or NCORP status, or how many patients a site enrolled. Use it as a second check after the official NCI and group rosters.
What is a CTEP site code, and why does it matter?
It is a unique code NCI assigns to each clinical site in its sponsored trials. Because the same hospital can appear under different names, the code is the most reliable way to match it across directories. Each group shows it under a different label, and some do not show it at all.
References
- [1]National Cancer Institute. "About NCI: Overview and Mission." cancer.gov. https://www.cancer.gov/about-nci/overview
- [2]National Cancer Institute. "NCI at a Glance." cancer.gov. https://www.cancer.gov/about-nci/overview/nci-at-a-glance
- [3]National Cancer Institute, Division of Cancer Treatment and Diagnosis. "NCTN: NCI's National Clinical Trials Network." dctd.cancer.gov. https://dctd.cancer.gov/research/networks/nctn
- [4]National Cancer Institute. "NCI Community Oncology Research Program (NCORP)." cancer.gov. Last updated August 20, 2019. https://www.cancer.gov/research/infrastructure/clinical-trials/ncorp
- [5]National Cancer Institute. "NCI's Clinical Trials Programs and Initiatives." cancer.gov. https://www.cancer.gov/research/infrastructure/clinical-trials
- [6]National Cancer Institute, Division of Cancer Treatment and Diagnosis. "CTEP Resources for Clinical Trials in NCI Networks." dctd.cancer.gov. https://dctd.cancer.gov/research/ctep-trials
- [7]National Cancer Institute. "NCI's National Clinical Trials Network (NCTN)." cancer.gov. Last updated February 27, 2026. https://www.cancer.gov/research/infrastructure/clinical-trials/nctn
- [8]National Cancer Institute. "Implementation of the NCI's National Clinical Trials Network." Press release, March 20, 2014. https://www.cancer.gov/news-events/press-releases/2014/nctnlaunch
- [9]National Cancer Institute. "How Clinical Trials Work." cancer.gov. https://www.cancer.gov/research/participate/clinical-trials/how-trials-work
- [10]National Cancer Institute, Division of Cancer Treatment and Diagnosis. "NCTN Organization." dctd.cancer.gov. Last updated July 31, 2026. https://dctd.cancer.gov/research/networks/nctn/organization
- [11]SWOG Cancer Research Network. "CTEP Site (Institution) Codes." swog.org. https://www.swog.org/member-resources/membership/institutional-membership/ctep-site-institution-codes
- [12]Alliance for Clinical Trials in Oncology. "What We Do." allianceforclinicaltrialsinoncology.org. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=/Public/About
- [13]Alliance for Clinical Trials in Oncology. "Member Institutions." allianceforclinicaltrialsinoncology.org. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=/Public/Institutions
- [14]Coalition of Cancer Cooperative Groups. "ECOG-ACRIN Cancer Research Group." coccg.org. https://coccg.org/coalition/ecog-acrin-cancer-research-group/
- [15]ECOG-ACRIN Cancer Research Group. "About Us." ecog-acrin.org. https://ecog-acrin.org/about-ecog-acrin-cancer-research-group/
- [16]ECOG-ACRIN Cancer Research Group. "Find a Participating Institution." ecog-acrin.org. https://ecog-acrin.org/participating-institutions/
- [17]NRG Oncology. "About Us." nrgoncology.org. https://www.nrgoncology.org/About-Us
- [18]NRG Oncology. "Member Institution Lists." nrgoncology.org. https://www.nrgoncology.org/about-us/member-institution-lists/
- [19]NRG Oncology. "NRG Oncology Main Member / LAPS / NCORP Institutions as of 7/1/2026." nrgoncology.org. https://www.nrgoncology.org/wp-content/uploads/2026/07/NRG-Main-Members-LAPS-NCORP-for-NRG-website.pdf
- [20]SWOG Cancer Research Network. "History & Impact." swog.org. https://www.swog.org/about/history-impact
- [21]SWOG Cancer Research Network. "Our Network." swog.org. https://www.swog.org/our-network
- [22]SWOG Cancer Research Network. "Institutions." swog.org. https://www.swog.org/clinical-trials/institutions
- [23]Children's Oncology Group. "About." childrensoncologygroup.org. https://childrensoncologygroup.org/about/
- [24]Children's Oncology Group. "COG Member Institutions." childrensoncologygroup.org. https://childrensoncologygroup.org/patients-families/member-institutions/
- [25]National Institutes of Health. "RFA-CA-24-033: NCI National Clinical Trials Network, Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed)." NIH Guide for Grants and Contracts (expired February 25, 2025). https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-033.html
- [26]National Cancer Institute, Division of Cancer Treatment and Diagnosis. "CTEP ETCTN." dctd.cancer.gov. https://dctd.cancer.gov/research/networks/etctn
- [27]National Cancer Institute, Division of Cancer Treatment and Diagnosis. "ETCTN Organization." dctd.cancer.gov. Last updated August 5, 2025. https://dctd.cancer.gov/research/networks/etctn/organization
- [28]National Cancer Institute, Division of Cancer Prevention. "NCI Community Oncology Research Program (NCORP)." prevention.cancer.gov. https://prevention.cancer.gov/research-areas/networks-consortia-programs/ncorp
- [29]National Cancer Institute. "NCORP Sites" (Find a Site). ncorp.cancer.gov. https://ncorp.cancer.gov/findasite/index.php
- [30]National Institutes of Health. "RFA-CA-27-008: NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed)." Full announcement. https://files.simpler.grants.gov/opportunities/e749b186-9043-4eb2-9288-4833ede537f7/attachments/4c389a46-f2d7-4527-90c6-e0945b90ec68/RFA-CA-27-008-Full-Announcement.html
- [31]National Cancer Institute, Division of Cancer Treatment and Diagnosis. "Resources for Network Sites." dctd.cancer.gov. https://dctd.cancer.gov/research/ctep-trials/for-sites
- [32]NCI Central Institutional Review Board. "About the CIRB." ncicirb.org. https://www.ncicirb.org/about-cirb
- [33]National Cancer Institute, Division of Cancer Treatment and Diagnosis. "CTEP Trial Development and Conduct." dctd.cancer.gov. Last updated July 16, 2026. https://dctd.cancer.gov/research/ctep-trials/trial-development
- [34]National Cancer Institute. "NCI National Clinical Trials Network (NCTN) Structure." cancer.gov. https://www.cancer.gov/research/infrastructure/clinical-trials/nctn/nctn-clinical-trials-network
- [35]National Cancer Institute. "Who Pays for Clinical Trials?" cancer.gov. https://www.cancer.gov/research/participate/clinical-trials/paying
- [36]ClinicalTrials.gov. "Policy: Data Element Definitions for Registration and Results Information." clinicaltrials.gov. https://clinicaltrials.gov/policy#data-element-definitions
